T 900607

Drug Profile

T 900607

Alternative Names: T 607; T900607; T900607-sodium

Latest Information Update: 23 Dec 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tularik
  • Developer Amgen
  • Class Antineoplastics; Sulfonamides
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Gastric cancer; Hepatocellular carcinoma; Non-Hodgkin's lymphoma; Oesophageal cancer; Ovarian cancer

Most Recent Events

  • 23 Dec 2004 Discontinued - Phase-I for Cancer in Canada (IV)
  • 23 Dec 2004 Discontinued - Phase-I for Cancer in United Kingdom (IV)
  • 23 Dec 2004 Discontinued - Phase-II for Gastric cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top